Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium

Current Medical Research and Opinion

Volumn 22, Issue 6, 2006, Pages 1133-1140

  Waterbury, L David ^a,c   Silliman, David ^a   Jolas, Thierry ^b  

^a Pacific BioLabs   (United States)

^b Cerep   (France)

^c NONE   (United States)

Author keywords

Anti inflammatory; Bromfenac; COX 1; COX 2; Ketorolac; NSAIDs; Ophthalmic

Indexed keywords

ARACHIDONIC ACID; BROMFENAC; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DRUG VEHICLE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; KETOROLAC TROMETAMOL; LIPOPOLYSACCHARIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTERIOR EYE CHAMBER; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFLAMMATION; FLUOROPHOTOMETRY; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; NONHUMAN; SYSTEMIC CIRCULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZOPHENONES; BROMOBENZENES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENZYME ACTIVATION; EYE DISEASES; HUMANS; INFLAMMATION; KETOROLAC TROMETHAMINE; RABBITS; RECOMBINANT PROTEINS;

EID: 33745685717     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X112471     Document Type: Article

References (41)

1. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1-11
2. Samiy N, Foster CS. The role of nonsteroidal antiinflammatory drugs in ocular inflammation. Int Ophthalmol Clin 1996;36:195-206
3. Koay P. The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology. Br J Ophthalmol 1996;80:480-5
4. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004;18:790-804
5. Malhotra S, Shafiq N, Pandhi P. COX-2 inhibitors: a class act or just vigorously promoted. MedGenMed 2004;6:6
6. Scott TE. Pharmaceutical agents for the treatment of rheumatoid arthritis. Manag Care 2001;10(Suppl):2-9
7. Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf 2002;25:633-48
8. Fry SW, Seeff LB. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am 1995;24:875-905
9. FDA Public Health Advisory. FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available from http://www.fda.gov/cder/drug/ advisory/COX2. htm [Last accessed 17 Aug 2005]
10. Schuman JS. Short- and long-term safety of glaucoma drugs. Expert Opin Drug Saf 2002;1:181-94
11. Fraunfelder FT, Morgan RL, Yunis AA. Blood dyscrasias and topical ophthalmic chloramphenicol. Am J Ophthalmol 1993;115:812-3
12. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol 1987;103:479-86
13. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514-19
14. Flach AJ, Lavelle CJ, Olander KW, et al. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology 1988;95:1279-84
15. Flach AJ, Stegman RC, Graham J, et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double-masked study. Ophthalmology 1990;97:1253-8
16. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg 1999;25:699-70
17. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: A randomized, vehicle-controlled clinical trial. Am J Ophthalmol 1999;127:253-9
18. Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001;108:331-7
19. Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther 2000;17:94-102
20. Sharma A, Gupta R, Ram J, et al. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis. Indian J Ophthalmol 1997;45:177-80
21. Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(Suppl):141-8
22. Tinkelman DG, Rupp G, Kaufman H, et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38(Suppl):133-40
23. Srinivasan BD, Kulkarni PS. Inhibitors of the arachidonic acid cascade in the management of ocular inflammation. Prog Clin Biol Res 1989;312:229-49
24. Snyder RW, Siekert RW, Schwiegerling J, et al. Acular® as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 2000;26:1225-7
25. Solomon KD, Donnenfeld ED, Raizman M, et al., for the Ketorolac Reformulation Study Groups 1 and 2. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg 2004;30:1653-60
26. ACULAR LS™ (ketorolac tromethamine ophthalmic solution) 0.4% sterile, product labeling. ©2003, Allergan, Irvine, CA, USA
27. Price MO, Price FW. Efficacy of topical ketorolac tromethamine 0.4% for control of pain or discomfort associated with cataract surgery. Curr Med Res Opin 2004;20:2015-9
28. Jett MF, Ramesha CS, Brown CD, et al. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther 1999;288:1288-97
29. Pallapies D, Salinger A, Meyer zum Gottesberge A, et al. Effects of lysine clonixinate and ketorolac tromethamine on prostanoid release from various rat organs incubated ex vivo. Life Sci 1995;57:83-9
30. XIBROM™ (bromfenac ophthalmic solution) 0.09%, product labeling. ©2003, Ista Pharmaceuticals, Irvine, CA, USA
31. Donnenfeld E, Holland EJ, Stewart R, et al. and the Bromfenac Study Group. Topical Xibrom™ 0.1%, and investigational NSAID, significantly and rapidly decreased post-cataract surgery inflammation and reduced ocular pain. Invest Ophthalmol Vis Sci 2005;46:791
32. Miyake-Kashima M, Takano Y, Tanaka M, et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn J Ophthalmol 2004;48:587-90
33. Waterbury LD, Flach AJ. Efficacy of low concentrations of ketorolac tromethamine in animal models of ocular inflammation. J Ocul Pharmacol Ther 2004;20:345-52
34. Warner TD, Giuliano F, Vojnovic, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999;96:7563-8
35. Schoenwald RD, Zhu J. The ocular pharmacokinetics of ketanserin and its metabolite, ketanserinol, in albino rabbits. J Ocul Pharmacol Ther 2000;16:481-95
36. Moses PL, Schroeder B, Alkhatib O, et al. Severe hepatotoxicity associated with bromfenac sodium. Am J Gastroenterol 1999;94:1393-6
37. Fontana RJ, McCashland TM, Benner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg 1999;5:480-4
38. Rabkin JM, Smith MJ, Orloff SL, et al. Fatal fulminant hepatitis associated with bromfenac use. Ann Pharmacother 1999;33:945-7
39. Skjodt NM, Davies NM. Clinical pharmacokinetics and pharmacodynamics of bromfenac. Clin Pharmacokinet 1999;36:399-408
40. Toradol (ketorolac tromethamine) product labeling. ©1997-2002, Roche Laboratories, Inc
41. BRONUK ophthalmic solution, product labeling. ©2003, Senju Pharmaceutical Co, Ltd, Osaka, Japan